Pharmacological treatment of non-cognitive disturbances in dementia disorders

Mechanisms of Ageing and Development

Volumn 122, Issue 16, 2001, Pages 2063-2069

  Parnetti, Lucilla ^a   Amici, Serena ^a   Lanari, Alessia ^a   Gallai, Virgilio ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Acetylcholinesterase inhibitors; Alzheimer's disease; Atypical antipsychotics; Behavioural symptoms; Serotonin reuptake inhibitors

Indexed keywords

ACETYLCHOLINE; BENZODIAZEPINE; CARBAMAZEPINE; CHOLINESTERASE INHIBITOR; CITALOPRAM; CLOZAPINE; DONEPEZIL; DOPAMINE; FLUOXETINE; FLUVOXAMINE; METRIFONATE; NEUROLEPTIC AGENT; NEUROTRANSMITTER; NORADRENALIN; OLANZAPINE; PAROXETINE; PHYSOSTIGMINE; QUETIAPINE; RISPERIDONE; RIVASTIGMINE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TACRINE; VALPROIC ACID;

ALZHEIMER DISEASE; BEHAVIOR; BRAIN METABOLISM; CONFERENCE PAPER; DEMENTIA; DISEASE SEVERITY; DORSAL RAPHE NUCLEUS; DRUG CHOICE; EMOTION; HEALTH CARE COST; HUMAN; INSTITUTIONALIZATION; LOCUS CERULEUS; NEUROCHEMISTRY; PRIORITY JOURNAL; QUALITY OF LIFE; SUBICULUM; SYMPTOMATOLOGY;

ALZHEIMER DISEASE; BEHAVIOR; COGNITION; HUMANS;

EID: 0034816916     PISSN: 00476374     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0047-6374(01)00316-5     Document Type: Conference Paper

References (25)

1. Practice guideline for the treatment of patients with Alzheimer's disease and other dementias of late life
2. Double-blind, placebo-controlled study of metrifonate, an acetylcholinesterase inhibitor, for Alzheimer disease
3. Physostigmine ameliorates the delusions of Alzheimer's disease
4. Antipsychotic agents in patients with dementia
5. Role of neuroleptics in treatment of behavioral complications
6. The signs of the behavioural and psychological symptoms of dementia
7. Behavioral and psychological signs and symptoms of dementia: A consensus statement on current knowledge and implications for research and treatment
8. Differential diagnosis of dementia. The clinical process
9. Neuropathological correlates of psychotic phenomena in confirmed Alzheimer's disease
10. Behavioral syndromes in Alzheimer's disease: Description and correlates
11. Cholinergic therapy of behavioral disturbances in Alzheimer's disease
12. Special workshop in dementia with Lewy bodies
13. Biologic markers and neurochemical correlates of agitation and psychosis in dementia
14. Long-term tacrine (Cognex) treatment: Effects on nursing home placement and mortality, Tacrine Study Group
15. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease
16. Effect of tacrine on language, praxis, and noncognitive behavioral problems in Alzheimer disease
17. The efficacy and safety of donepezil in patients with Alzheimer's disease: Results of a US multicentre, randomized, double-blind, placebo-controlled trial
18. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease
19. Guidelines for the appropriate use of cholinesterase inhibitors in patients with Alzheimer's disease
20. A metaanalysis of controlled trials of neuroleptic treatment in dementia
21. The use of psychotropic medication in the management of problem behaviors in the patient with Alzheimer's disease
22. Neuroimaging and the origin of psychiatric symptoms in dementia
23. Neuropathologic and neurochemical correlates of psychosis in primary dementia